AR and neoplasm: Despite great benefits and improvements in patients’ survival outcomes, once on ADT the development of mCRPC is just a matter of time and an adaptive mechanism for tumor cells to maintain high intracellular androgen level and overexpress androgen receptor (AR) has been observed in mCRPC [1].